Fingerprint
Dive into the research topics of 'Alemtuzumab as Second-Line Treatment for Late Antibody-Mediated Rejection of Transplanted Kidneys'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Alemtuzumab as Second-Line Treatment for Late Antibody-Mediated Rejection of Transplanted Kidneys
Michiel G.H. Betjes*, Marcia M.L. Kho, Nicolle H.R. Litjens, Annelies E. de Weerd, Joke I. Roodnat
*Corresponding author for this work
Research output: Contribution to journal › Article › Academic › peer-review
9
Citations
(Scopus)
86
Downloads
(Pure)